Acinic Cell Carcinoma: Rare Lung Cancer Insights in Taiwan - Pulmonology

Share to:

Questions related to acinic cell carcinoma?


Hello, my friend was recently diagnosed with acinic cell carcinoma located in the lungs.
I couldn't find any related cases in Taiwan online, and since it's in the lungs, it's even rarer.
I'm unsure if this is considered a rare disease in Taiwan, so I would like to inquire about relevant information.
Is there a way to treat it?

Xiao Tang, 20~29 year old female. Ask Date: 2013/01/16

Dr. Huang Ruiming reply Pulmonology


Hello, Xiao Tang: Acinic cell carcinoma is extremely rare as a primary cancer in the lungs; most cases are metastatic from other sites, such as the salivary glands or parotid glands.
Its treatment typically follows the standard cancer protocols, which include surgical resection, radiation therapy, and chemotherapy.
Generally, the prognosis for metastatic cancer is poor, and if it further metastasizes to the brain, the prognosis is very unfavorable.
Thank you for your inquiry.
This response is from Dr.
Huang Ruiming, Department of Pulmonary Medicine.

Reply Date: 2013/01/16

More Info


Acinic cell carcinoma (ACC) is a rare type of cancer that primarily originates in the salivary glands, particularly the parotid gland. However, it can also occur in other locations, including the lungs, although this is exceedingly rare. The occurrence of ACC in the lungs is not well-documented, and most cases are typically metastatic, meaning they originate from another site, such as the salivary glands, and spread to the lungs.
In Taiwan, as in many parts of the world, lung cancers are more commonly associated with types such as adenocarcinoma, squamous cell carcinoma, and small cell lung cancer. The rarity of ACC in the lung makes it challenging to find extensive literature or case studies specific to this condition in Taiwan. This lack of data can lead to uncertainty regarding treatment options and prognosis.


Treatment Options
The treatment for acinic cell carcinoma, regardless of its primary site, generally follows the standard protocols for cancer treatment, which include:
1. Surgical Resection: If the tumor is localized and operable, surgical removal is often the first line of treatment. The goal is to achieve clear margins, meaning no cancer cells are present at the edges of the removed tissue.

2. Radiation Therapy: This may be recommended post-surgery, especially if there is a risk of residual disease or if the tumor is of a higher grade. Radiation can help to eliminate any remaining cancer cells.

3. Chemotherapy: While ACC is typically less responsive to chemotherapy compared to other more common lung cancers, it may still be considered, particularly in cases where the cancer is advanced or has metastasized.

4. Targeted Therapy: Depending on the specific genetic and molecular characteristics of the tumor, targeted therapies may be an option. However, this would require genetic testing of the tumor.


Prognosis
The prognosis for acinic cell carcinoma can vary significantly based on several factors, including the tumor's location, size, grade, and whether it has metastasized. Generally, localized tumors that are completely resected have a better prognosis. However, once the cancer has spread to lymph nodes or other organs, the prognosis tends to worsen.

In the case of lung involvement, if the ACC is indeed a primary lung tumor, the prognosis may be less favorable than for salivary gland tumors due to the aggressive nature of lung cancers and the potential for late diagnosis.

Conclusion
In summary, acinic cell carcinoma in the lungs is a rare and complex condition. Treatment typically involves surgery, possibly followed by radiation or chemotherapy, depending on the individual case. The prognosis can vary widely, and it is crucial for your friend to work closely with a medical team that specializes in oncology to determine the best course of action. Given the rarity of this cancer type, seeking a second opinion or consulting with a specialist who has experience with rare lung cancers may also be beneficial.
Encourage your friend to maintain open communication with their healthcare providers and to ask questions about their treatment options, potential clinical trials, and any supportive care services that may be available.

Similar Q&A

Latest Advances in Lung Cancer Treatment: New Drug Impact and Availability in Taiwan

A few days ago, a news report stated that lung cancer is the leading cause of death among the top ten causes. Recently, a certain country discovered an effective medication that significantly helps patients with advanced lung cancer. I would like to know if this medication has be...


Dr. Li Huixiong reply Internal Medicine
Lung cancer has consistently ranked among the top three causes of cancer-related deaths for both men and women in Taiwan over the past three years, with a trend of increasing incidence. The treatment and prognosis of lung cancer are significantly related to its staging (TNM Stagi...

[Read More] Latest Advances in Lung Cancer Treatment: New Drug Impact and Availability in Taiwan


Understanding Lung Adenocarcinoma: Insights on Diagnosis and Prognosis

GROSS FINDING: The entire specimen is embedded in 2 blocks. Immunostaining for TTF-1 is performed on block A (HBH). MICROSCOPIC FINDING: Sections show desmoplastic stroma with infiltrating non-mucinous, TRU type adenocarcinoma cells in an acinar growth pattern. The tumor cells ...


Dr. Zhou Ziguang reply Pulmonology
Hello: Prognosis is related to the extent of tumor spread and specific biochemical/immunological markers. It is advisable to discuss this in detail with your attending physician to determine the subsequent management plan.

[Read More] Understanding Lung Adenocarcinoma: Insights on Diagnosis and Prognosis


Understanding Stage IA1 Lung Adenocarcinoma and Tumor Marker Abnormalities

Hello Doctor, this is my mother's pathology report from that time. NOMED: 28000-B-M81403, 29000-B-M09450 DX: Lung, right middle lobe, wedge resection - Invasive acinar adenocarcinoma, moderately differentiated (G2) AJCC 8TH Pathological stage: IA1 (pT1a Nx) (also refer...


Dr. Chen Sirong reply Oncology
Huang, 27 years old, male, has been diagnosed with stage I lung cancer. The Cyfra 21-1 level is 4.11, which is greater than the standard of 3.3 (first test). It is advisable to conduct follow-up testing for Cyfra 21-1 earlier, which is out-of-pocket, so you can have it checked ev...

[Read More] Understanding Stage IA1 Lung Adenocarcinoma and Tumor Marker Abnormalities


Understanding the Differences in MPN Classification: Taiwan vs. Global Perspectives

Hello, Doctor. Thank you for your response yesterday, but it did not address my concerns. I have reviewed many original literature and studies from various countries, such as the UK, Canada, and the USA, which classify Myeloproliferative Neoplasms (MPNs) as cancer. The term "...


Dr. Chen Yunfang reply Oncology
Hello: I am a specialist in hematology, and I do not agree that myeloproliferative neoplasms (MPNs) are classified as cancer. I am not sure why other countries do this, and I do not wish to explain their actions. In any case, Taiwan is the only country with a national health insu...

[Read More] Understanding the Differences in MPN Classification: Taiwan vs. Global Perspectives


Related FAQ

Lung Adenocarcinoma

(Pulmonology)

Lung Cancer

(Oncology)

Lung Nodule

(Pulmonology)

Ct Report

(Pulmonology)

Ground-Glass Nodule

(Pulmonology)

Covid-19

(Pulmonology)

Lungs

(Internal Medicine)

Pancreatic Cancer

(Oncology)

Purpura

(Oncology)

Smoking Cessation

(Pulmonology)